Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232663 | 1.00 | PTGER4 (0.43) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL29640531 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL31463429 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL29640529 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL24455263 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25279173 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25404705 | 0.88 | KMT2A (0.40) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL24960037 | 0.88 | ALDH1A1 (0.41) | PTGER4KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL29159913 | 0.88 | ALDH1A1 (0.41) | PTGER4KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL27176929 | 0.88 | KDM4E (0.42) | PTGER4KMT2AHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2023001237-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | PTGER4 1906/4885KMT2A 1759/4885HPGD 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.